News-Medical.Net on MSN
Human insight and AI advance prostate cancer treatment
Today, many men must choose between life-altering prostate removal or careful long-term monitoring. The EU-funded ROBIOSPY ...
Osaka, Japan - A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray ...
Hosted on MSN
J&J eyes prostate cancer label expansion for Akeega
Johnson & Johnson (J&J) has applied to the European Medicines Agency (EMA) to extend the indication of Akeega (niraparib and abiraterone acetate) in prostate cancer. Akeega has been approved in Europe ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
A new paper in the Journal of the National Cancer Institute indicates that patients may benefit if doctors stop calling certain early-stage changes to the prostate "cancer" at all. The paper is titled ...
The FDA approved updated labeling for Talzenna plus Xtandi for HRR gene-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial results. The TALAPRO-2 trial showed a ...
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...
Pfizer PFE announced that the FDA approved the expansion of its PARP inhibitor Talzenna (talazoparib) in prostate cancer indication. The regulatory agency approved the combination of Talzenna with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results